This paper analyzes the financial position of ImmuLogic Pharmaceutical Corporation, a four-year-old biotech firm that had yet to bring a commercially viable product to market, as it considered proceeding with an initial public offering (IPO) targeting $80 million in capital. Using data drawn from the company's financial statements for 1989 and 1990, the paper computes key financial ratios — including the quick ratio, current ratio, asset turnover, and return on assets — to assess the firm's short-term liquidity and profitability trajectory. The analysis projects forward four years under the same deterioration rates, demonstrating that without the IPO proceeds, the company faces exponential losses and severe asset depletion. The paper ultimately argues that proceeding with the IPO is financially necessary and strategically sound.
ImmuLogic Pharmaceutical Corporation is a relatively young firm with only four years of experience in the market. The organization nevertheless possesses significant growth potential and has decided to pursue an initial public offering (IPO) in an effort to generate an expected $80 million in capital. However, in a context where the firm does not yet have a commercially viable product — and bringing one to market would require an additional four years — serious questions arise regarding the future sustainability of the offering. Specifically, the company's executives are weighing whether to proceed with the IPO or withdraw it.
Providing a well-grounded answer to this question is an intricate endeavor, dependent on a multitude of factors. At the initial level, however, the analysis relies on objective quantitative features conducted through numerical data, which lead to relevant and unbiased conclusions (Balnaves and Caputi, 2001). Several financial computations are completed to assess the financial strength of ImmuLogic Pharmaceutical Corporation, using data collected from the firm's financial statements.
Quick ratio = (Current assets − Inventories) / Current liabilities
Note: Since ImmuLogic Pharmaceutical Corporation does not have a commercially viable product, its inventories are assumed to be zero.
Quick ratio = Current assets / Current liabilities
Quick ratio in 1989 = 20,466 / 877 = 23.34
Quick ratio in 1990 = 15,142 / 890 = 17.01
The quick ratio portrays the company's short-term liquidity — specifically, its ability to pay short-term obligations with its most liquid assets (Investopedia, 2012). The computation of both years' ratios reveals that the company's ability to pay its short-term debts decreased in 1990 relative to the previous year.
Current ratio = Current assets / Current liabilities
Note: Since ImmuLogic Pharmaceutical Corporation does not carry inventories, its current ratio equals its quick ratio, as follows:
Current ratio in 1989 = 20,466 / 877 = 23.34
Current ratio in 1990 = 15,142 / 890 = 17.01
The current ratio, also known as the liquidity ratio, is an indicator of a company's ability to pay its short-term obligations (Investopedia, 2012). As these computations reveal, the pharmaceutical company encountered a decline in its ability to honor short-term obligations in 1990 relative to the previous year. Nevertheless, both ratios remain very high, indicating that the firm retained substantial liquidity in the near term.
Asset turnover = Revenues / Total assets
Asset turnover in 1989 = −3,145 / 24,128 = −0.13
Asset turnover in 1990 = −6,043 / 18,604 = −0.32
From this ratio, it becomes clear that the company's financial results suffered significant deterioration in 1990 relative to 1989. The organization registered a substantial decrease in assets alongside a near-doubling of its net losses, further deepening its negative financial results. These outcomes are explained by the fact that the company is still in the research and investment phase and has yet to capitalize on its investments. At this rate, the financial sustainability of the organization is questionable.
The asset turnover ratio measures a company's ability to use its assets to generate sales and, subsequently, profits (Asset Turnover, 2011). In the case of ImmuLogic Pharmaceutical Corporation, this ability decreased significantly from 1989 to 1990, reflecting a severely reduced capacity to convert assets into positive financial results.
The return on assets (ROA) ratio is traditionally computed by dividing net income by total assets. In the specific case of ImmuLogic Pharmaceutical Corporation, the return on assets equals the asset turnover, since the company does not register any sales revenues — only net losses resulting from continued investment activities. Accordingly:
Return on assets in 1989 = −3,145 / 24,128 = −0.13
Return on assets in 1990 = −6,043 / 18,604 = −0.32
Return on assets traditionally assesses the profitability of a firm relative to its total assets (Investopedia, 2012). In the case of ImmuLogic Pharmaceutical Corporation, the organizational ability to generate profits is diminished, a direct consequence of the absence of a product available for sale.
Since ImmuLogic Pharmaceutical Corporation does not yet carry equity, the computation of several other ratios is not possible. For instance, it is impossible to compute the debt-to-equity ratio or earnings per share. In this context, the majority of the ratios computed are most useful for assessing the quality and efficiency of management at the firm rather than its market profitability. Furthermore, since the ratios are computed for two consecutive years — 1989 and 1990 — they help paint a picture of the company's year-over-year evolution.
In general, the financial position and strength of ImmuLogic Pharmaceutical Corporation in 1990 decreased relative to 1989. Organizational assets declined and final results weakened. As the asset turnover and return on assets ratios indicate — as depicted in the firm's financial statements — the financial results of ImmuLogic are weak and deteriorated significantly in 1990 relative to the prior year.
This situation is due to the fact that the company's results are entirely negative, reflecting only the investments made in product development while the firm remains unable to complete and commercialize a product that would generate tangible revenues. Furthermore, given that the company estimates an additional four years before a commercially feasible product is ready, its position would be placed under further strain. To illustrate this risk, assume the following observed deterioration rates continue unchanged:
The organizational assets decreased from 1989 to 1990 from $24,128,000 to $18,604,000, representing a 22.89% decrease (i.e., a retention rate of approximately 77%).
The organizational net losses deepened from −$3,145,000 in 1989 to −$6,043,000 in 1990, representing a 92.14% increase in losses (i.e., a growth factor of approximately 1.92×).
Applying these rates forward over the next four years yields the following projections:
Projected Assets:
Assets in 1991 = 18,604,000 × 0.77 = 14,325,080
"Four-year projections show exponential losses ahead"
Investors may contribute their own expertise and networks to support the growth and development of the corporation.
A successful IPO opens the possibility of raising additional investment in the future from the same investor base, provided confidence in the entity is maintained (Business Link).
In sum, the quantitative analysis of ImmuLogic's financial position, combined with forward-looking projections, makes a compelling case that the IPO is not merely a strategic option but a financial necessity for the firm's survival and eventual commercialization of its product pipeline.
Balnaves, M., Caputi, P., 2001, Introduction to Quantitative Research Methods: An Investigative Approach, SAGE.
Lerner, J., 1992, ImmuLogic Pharmaceutical Corporation, Harvard Business School.
Asset Turnover, 2011, Asset turnover definition, Last accessed February 6, 2012.
Investopedia, 2012, Last accessed February 6, 2012.
Business Link, Equity finance, http://www.businesslink.gov.uk. Last accessed February 6, 2012.
You’re 81% through this paper. Sign up to read the remaining 1 section.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.